Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Idera, Silence, OSU, and More


Title: miR-182-, miR-191-, miR-199a-based Methods for the Diagnosis and Prognosis of Acute Myeloid Leukemia

Patent Number: 8,431,342

Filed: Oct. 7, 2011

Inventor: Carlo Croce, Ohio State University

The invention, the patent’s abstract states, provides “novel methods and compositions for the diagnosis, prognosis, and treatment of acute myeloid leukemia.”

Title: microRNAs that Regulate Muscle Cell Proliferations and Differentiation

Patent Number: 8,431,542

Filed: Dec. 12, 2006

Lead Inventor: Da-Zhi Wang, University of North Carolina, Chapel Hill

The invention relates to “methods and compositions for modulating gene expression in myocytes,” and "provides cells comprising the compositions," according to the patent’s abstract.

Title: Compositions for Inhibiting Gene Expression and Uses Thereof

Patent Number: 8,431,544

Filed: Aug. 26, 2010

Lead Inventor: Sudhir Agrawal, Idera Pharmaceuticals

The invention, the patent’s abstract states, relates to “new structural features that … improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3' ends and a linker at the 5' ends. … These features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. … This effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.”

Title: General Composition Framework for Ligand-Controlled RNA Regulatory Systems

Application Number: 20130102651

Filed: Aug. 15, 2012

Lead Inventor: Christina Smolke, California Institute of Technology

The invention, the patent application’s abstract states, provides “an improved design for the construction of extensible nucleic acid-based, ligand-controlled regulatory systems, and the nucleic acid regulatory systems resulting therefrom. The invention contemplates improving the design of the switches through the design of an information transmission domain. The improved ITD eliminates free-floating ends of the switching and the competing strands, and localizes competitive hybridization events to a contiguous strand of competing and switching strands in a strand-displacement mechanism-based switch, thereby improving the kinetics of strand displacement. The improved regulatory systems have many uses in various biological systems, including gene expression control or ligand-concentration sensing.”

Title: Methods and Compositions Related to Modified Adenosines for Controlling Off-Target Effects in RNA Interference

Application Number: 20130102652

Filed: March 23, 2011

Lead Inventor: Cynthia Burrows, University of Utah

The invention comprises “compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs … [as well as] compositions and methods related to modified adenonsine for controlling off-target effects in RNA interference.”

Title: Interfering RNA Molecules

Application Number: 20130102769

Filed: Dec. 3, 2012

Lead Inventor: Klaus Giese, Silence Therapeutics

The invention, the patent application’s abstract states, “is related to a ribonucleic acid comprising a double-stranded structure … whereby the first strand comprises a … stretch of contiguous nucleotides [that] … is at least partially complementary to a target nucleic acid, and the second strand comprises a … stretch of contiguous nucleotides … at least partially identical to a target nucleic acid. … The double stranded structure is blunt-ended.”